{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:00:53Z","timestamp":1792598453834,"version":"4.5.0"},"reference-count":148,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chronic inflammatory skin diseases are multifactorial diseases that combine genetic predisposition, environmental triggers, and metabolic disturbances associated with abnormal immune responses. From an immunological perspective, the better understanding of their physiopathology has demonstrated a large complex network of immune cell subsets and related cytokines that interact with both epidermal and dermal cells. For example, in type-1-associated diseases such as alopecia areata, vitiligo, and localized scleroderma, recent evidence suggests the presence of a type-2 inflammation that is well known in atopic dermatitis. Whether this type-2 immune response has a protective or detrimental impact on the development and chronicity of these diseases remains to be fully elucidated, highlighting the need to better understand its involvement for the management of patients. This mini-review explores recent insights regarding the potential role of type-2-related immunity in alopecia areata, vitiligo, and localized scleroderma.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1405215","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T04:24:16Z","timestamp":1716956656000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?"],"prefix":"10.3389","volume":"15","author":[{"given":"Laure","family":"Migayron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Bordes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Closs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Boniface","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.11.001","article-title":"The 3 major types of innate and adaptive cell-mediated effector immunity","volume":"135","author":"Annunziato","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01009-w","article-title":"Repositioning TH cell polarization from single cytokines to complex help","volume":"22","author":"Tuzlak","year":"2021","journal-title":"Nat Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jaci.2013.03.050","article-title":"Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation","volume":"132","author":"Stott","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cyto.2015.05.010","article-title":"T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production","volume":"75","author":"Zhu","year":"2015","journal-title":"Cytokine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100131","DOI":"10.1016\/j.xjidi.2022.100131","article-title":"Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis","volume":"2","author":"Beck","year":"2022","journal-title":"JID Innov"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.04.101","article-title":"Group 2 innate lymphoid cells in airway diseases","volume":"156","author":"Kato","year":"2019","journal-title":"Chest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nri2199","article-title":"Protective immune mechanisms in helminth infection","volume":"7","author":"Anthony","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discovery"},{"key":"B10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.3390\/ijms21155382","article-title":"Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis","volume":"21","author":"Furue","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.74","article-title":"Th2 cytokines act on S100\/A11 to downregulate keratinocyte differentiation","volume":"128","author":"Howell","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1016\/j.jaci.2009.07.012","article-title":"Cytokine modulation of atopic dermatitis filaggrin skin expression","volume":"124","author":"Howell","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.3390\/ijms23042116","article-title":"An interleukin-4 and interleukin-13 induced atopic dermatitis human skin equivalent model by a skin-on-A-chip","volume":"23","author":"Kim","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/12034754221130969","article-title":"Treatment with dupilumab in patients with atopic dermatitis: systematic review and meta-analysis","volume":"26","author":"Koskeridis","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01583-1","article-title":"Tralokinumab: first approval","volume":"81","author":"Duggan","year":"2021","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: A phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"llae013","DOI":"10.1093\/ced\/llae013","article-title":"Real world outcomes of children treated with dupilumab for moderate-to severe atopic dermatitis: A single centre retrospective observational UK study","volume":"8","author":"Hosseini-Ashrafi","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/all.16009","article-title":"Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs","volume":"8","author":"M\u00fcller","year":"2024","journal-title":"Allergy"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01061-4","article-title":"Real-world effectiveness of dupilumab in adult and adolescent patients with atopic dermatitis: 2-year interim data from the PROSE registry","volume":"14","author":"Simpson","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19382","article-title":"Survival, efficacy and safety of tralokinumab after 32 and 52\u2009weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study","volume":"38","author":"Pezzolo","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2285243","DOI":"10.1080\/09546634.2023.2285243","article-title":"Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience","volume":"34","author":"Ferrucci","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad435","article-title":"Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials","volume":"190","author":"Yosipovitch","year":"2024","journal-title":"Br J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.06.042","article-title":"Lebrikizumab monotherapy for the treatment of moderate to severe atopic dermatitis","volume":"11","author":"Kimura","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00793-5","article-title":"Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis","volume":"24","author":"Bernardo","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00942-y","article-title":"Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: A 52-week, open-label, phase 3 study","volume":"13","author":"Paller","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.09.031","article-title":"Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood","volume":"145","author":"Czarnowicki","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.04.062","article-title":"Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers","volume":"147","author":"Bakker","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad032","article-title":"Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab","volume":"188","author":"Wu","year":"2023","journal-title":"Br J Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/ijms25010265","article-title":"How do classical subtypes correspond to endotypes in atopic dermatitis","volume":"25","author":"Suzuki","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1108623","article-title":"Morphea: the 2023 update","volume":"10","author":"Papara","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19912","article-title":"Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes","author":"Knobler","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14458","article-title":"European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes","volume":"31","author":"Knobler","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15811","article-title":"Localized scleroderma: actual insights and new biomarkers","volume":"61","author":"Snarskaya","year":"2022","journal-title":"Int J Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.04.009","article-title":"The role of skin trauma in the distribution of morphea lesions: a cross-sectional survey of the Morphea in Adults and Children cohort IV","volume":"71","author":"Grabell","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/art.38814","article-title":"Major histocompatibility complex class I and class II alleles may confer susceptibility to or protection against morphea: findings from the Morphea in Adults and Children cohort","volume":"66","author":"Jacobe","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200410","article-title":"Cellular infiltrates in scleroderma skin","volume":"20","author":"Fleischmajer","year":"1977","journal-title":"Arthritis Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.020","article-title":"Histopathological changes in morphea and their clinical correlates: Results from the Morphea in Adults and Children Cohort V","volume":"76","author":"Walker","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.669116","article-title":"Genetic signatures from RNA sequencing of pediatric localized scleroderma skin","volume":"9","author":"Mirizio","year":"2021","journal-title":"Front Pediatr"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.04.008","article-title":"Transcriptional and cytokine profiles identify CXCL9 as a biomarker of disease activity in morphea","volume":"137","author":"O\u2019Brien","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"R188","DOI":"10.1186\/ar4378","article-title":"Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma","volume":"15","author":"Magee","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"9796","DOI":"10.3390\/ijms24129796","article-title":"Single-cell transcriptome analysis identifies subclusters with inflammatory fibroblast responses in localized scleroderma","volume":"24","author":"Werner","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jid.2022.11.025","article-title":"CXCL9 links skin inflammation and fibrosis through CXCR3-dependent upregulation of col1a1 in fibroblasts","volume":"143","author":"Richmond","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"467808","DOI":"10.1155\/2013\/467808","article-title":"Updates on morphea: role of vascular injury and advances in treatment","volume":"2013","author":"Sartori-Valinotti","year":"2013","journal-title":"Autoimmune Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"174510","DOI":"10.1016\/j.ejphar.2021.174510","article-title":"TGF-\u03b2-induced fibrosis: A review on the underlying mechanism and potential therapeutic strategies","volume":"911","author":"Ong","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/art.22289","article-title":"Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192","volume":"56","author":"Denton","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/BF01262331","article-title":"Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma","volume":"287","author":"Ihn","year":"1995","journal-title":"Arch Dermatol Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0923-1811(99)00008-0","article-title":"Expression of TGF-beta 1, -beta 2 and -beta 3 in localized and systemic scleroderma","volume":"21","author":"Querfeld","year":"1999","journal-title":"J Dermatol Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1159\/000071783","article-title":"Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma","volume":"207","author":"Hasegawa","year":"2003","journal-title":"Dermatology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/art.37706","article-title":"Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis","volume":"65","author":"Fuschiotti","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"B58","article-title":"Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents","volume":"37","author":"Fertin","year":"1991","journal-title":"Cell Mol Biol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116015","article-title":"Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4","volume":"90","author":"Postlethwaite","year":"1992","journal-title":"J Clin Invest"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1042\/bj3070673","article-title":"Stimulation of sulphated glycosaminoglycan and decorin production in adult dermal fibroblasts by recombinant human interleukin-4","volume":"307","author":"Wegrowski","year":"1995","journal-title":"Biochem J"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/2000656X.2019.1612752","article-title":"Periostin is induced by IL-4\/IL-13 in dermal fibroblasts and promotes RhoA\/ROCK pathway-mediated TGF-\u03b21 secretion in abnormal scar formation","volume":"53","author":"Maeda","year":"2019","journal-title":"J Plast Surg Handb Surg"},{"key":"B62","article-title":"Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts","volume":"292","author":"Oriente","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-0420","article-title":"Effects of Th2 cytokines on expression of collagen, MMP-1, and TIMP-1 in conjunctival fibroblasts","volume":"44","author":"Leonardi","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B64","doi-asserted-by":"publisher","first-page":"154799","DOI":"10.1016\/j.cyto.2019.154799","article-title":"Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis","volume":"125","author":"Gasparini","year":"2020","journal-title":"Cytokine"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2001.00217.x","article-title":"Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes","volume":"116","author":"McGaha","year":"2001","journal-title":"J Invest Dermatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/(ISSN)1521-4141","article-title":"Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma","volume":"28","author":"Ong","year":"1998","journal-title":"Eur J Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.6.4020","article-title":"IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent","volume":"173","author":"Kaviratne","year":"2004","journal-title":"J Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1346-8138.16207","article-title":"Alopecia areata: Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines","volume":"49","author":"Fukuyama","year":"2022","journal-title":"J Dermatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501798","article-title":"CXCR3 blockade inhibits T cell migration into the skin and prevents development of alopecia areata","volume":"197","author":"Dai","year":"2016","journal-title":"J Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.04.031","article-title":"National Alopecia Areata Registry. History of atopy or autoimmunity increases risk of alopecia areata","volume":"61","author":"Barahmani","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2017.050","article-title":"Association among thyroid dysfunction, asthma, allergic rhinitis and eczema in children with alopecia areata","volume":"5","author":"Ghaffari","year":"2017","journal-title":"Open Access Maced J Med Sci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01676.x","article-title":"Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history","volume":"20","author":"Goh","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llac104","article-title":"Alopecia areata and risk of atopic and autoimmune conditions: population-based cohort study","volume":"48","author":"Holmes","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.01.052","article-title":"Alopecia areata is associated with atopic diathesis: results from a population-based study of 51,561 patients","volume":"8","author":"Kridin","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700915","article-title":"Loss-of-function mutations in the filaggrin gene and alopecia areata: strong risk factor for a severe course of disease in patients comorbid for atopic disease","volume":"127","author":"Betz","year":"2007","journal-title":"J Invest Dermatol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2013.05.086","article-title":"The association between Interleukin (IL)-4 gene intron 3 VNTR polymorphism and alopecia areata (AA) in Turkish population","volume":"527","author":"Kalkan","year":"2013","journal-title":"Gene"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.129","article-title":"Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance","volume":"132","author":"Jagielska","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094260","article-title":"Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata","volume":"9","author":"Bertolini","year":"2014","journal-title":"PloS One"},{"key":"B80","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12968-015-0112-6","article-title":"Single bolus versus split dose gadolinium administration in extra-cellular volume calculation at 3 Tesla","volume":"17","author":"McDiarmid","year":"2015","journal-title":"J Cardiovasc Magn Reson"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.06.032","article-title":"Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17\/TH22 skewing","volume":"136","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12918","article-title":"Biomarkers of alopecia areata disease activity and response to corticosteroid treatment","volume":"25","author":"Fuentes-Duculan","year":"2016","journal-title":"Exp Dermatol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.jaci.2018.06.029","article-title":"An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation","volume":"142","author":"Song","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12273","article-title":"Serum thymus and activation-regulated chemokine as disease activity and response biomarker in alopecia areata","volume":"40","author":"Inui","year":"2013","journal-title":"J Dermatol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.2013.169.issue-3","article-title":"T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata","volume":"169","author":"Tembhre","year":"2013","journal-title":"Br J Dermatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2005.01817.x","article-title":"In vitro cytokine profile in childhood alopecia areata and the immunomodulatory effects of AS-101","volume":"30","author":"Shohat","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-015-1539-1","article-title":"Lesional infiltration of mast cells, Langerhans cells, T cells and local cytokine profiles in alopecia areata","volume":"307","author":"Zhang","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18008","article-title":"Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity","volume":"182","author":"Bain","year":"2020","journal-title":"Br J Dermatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/all.13346","article-title":"Alopecia areata is characterized by expansion of circulating Th2\/Tc2\/Th22, within the skin-homing and systemic T-cell populations","volume":"73","author":"Czarnowicki","year":"2018","journal-title":"Allergy"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13023","article-title":"Dupilumab and alopecia: A Janus effect","volume":"32","author":"Patruno","year":"2019","journal-title":"Dermatol Ther"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14129","article-title":"Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata","volume":"29","author":"Ito","year":"2020","journal-title":"Exp Dermatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0542-7","article-title":"The changing landscape of alopecia areata: the therapeutic paradigm","volume":"34","author":"Renert-Yuval","year":"2017","journal-title":"Adv Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/cia2.12289","article-title":"Two-sided influence of dupilumab on alopecia areata co-existing with severe atopic dermatitis: A case series and literature review","volume":"6","author":"Fukuyama","year":"2023","journal-title":"J Cutaneous Imm Allergy"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.936488","article-title":"Long-term efficacy of dupilumab in alopecia areata","volume":"23","author":"Kulkarni","year":"2022","journal-title":"Am J Case Rep"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.10.010","article-title":"Drug-induced alopecia after dupilumab therapy","volume":"5","author":"Flanagan","year":"2019","journal-title":"JAAD Case Rep"},{"key":"B96","doi-asserted-by":"publisher","first-page":"adv00191","DOI":"10.2340\/00015555-3549","article-title":"Massive acute alopecia of the scalp in a patient treated with dupilumab","volume":"100","author":"Gallo","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.010","article-title":"Cause or cure? Review of dupilumab and alopecia areata","volume":"88","author":"Marks","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llac088","article-title":"\u201cI feel like a new woman\u201d: atopic dermatitis and alopecia areata treated successfully by dupilumab","volume":"48","author":"McFeely","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1253795","article-title":"Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib","volume":"10","author":"Cai","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16764","article-title":"Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study","volume":"50","author":"Napolitano","year":"2023","journal-title":"J Dermatol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/all.15071","article-title":"Phase 2a randomized clinical trial of dupilumab (anti-IL-4R\u03b1) for alopecia areata patients","volume":"77","author":"Guttman-Yassky","year":"2022","journal-title":"Allergy"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.3390\/ijms22052618","article-title":"Immunological properties of atopic dermatitis-associated alopecia areata","volume":"22","author":"Kageyama","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B103","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12016-017-8622-7","article-title":"Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy","volume":"54","author":"Boniface","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jaci.2016.10.013","article-title":"Oxidative stress drives CD8+ T-cell skin trafficking in patients with vitiligo through CXCL16 upregulation by activating the unfolded protein response in keratinocytes","volume":"140","author":"Li","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.09.015","article-title":"Vitiligo skin T cells are prone to produce type 1 and type 2 cytokines to induce melanocyte dysfunction and epidermal inflammatory response through jak signaling","volume":"142","author":"Martins","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/med.21754","article-title":"Mechanisms of melanocyte death in vitiligo","volume":"41","author":"Chen","year":"2021","journal-title":"Med Res Rev"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.08.038","article-title":"Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3","volume":"138","author":"Boniface","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.jid.2019.11.013","article-title":"NKG2D defines a subset of skin effector memory CD8 T cells with proinflammatory functions in vitiligo","volume":"140","author":"Jacquemin","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a expression defines tissue-resident CD8+ T cells poised for cytotoxic function in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.10.032","article-title":"Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo","volume":"139","author":"Richmond","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2012.1117","article-title":"CD8+ T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis","volume":"7","author":"Wu","year":"2013","journal-title":"Mol Med Rep"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2080","article-title":"Interferon-gamma inhibits melanogenesis and induces apoptosis in melanocytes: A pivotal role of CD8+ Cytotoxic T lymphocytes in vitiligo","volume":"95","author":"Yang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14016","article-title":"Tumour necrosis factor-\u03b1 inhibition can stabilize disease in progressive vitiligo","volume":"173","author":"Webb","year":"2015","journal-title":"Br J Dermatol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133772","article-title":"Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo","volume":"5","author":"Boukhedouni","year":"2020","journal-title":"JCI Insight"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.017","article-title":"Resident memory T cells in nonlesional skin and healed lesions of patients with chronic inflammatory diseases: Appearances can be deceptive","volume":"153","author":"Migayron","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.4228","article-title":"Association between vitiligo and atopic disorders: a pilot study","volume":"149","author":"Silverberg","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.03.030","article-title":"Atopic dermatitis and risk of autoimmune conditions: Population-based cohort study","volume":"150","author":"de Lusignan","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13263","article-title":"Association of atopic dermatitis with vitiligo: A systematic review and meta-analysis","volume":"19","author":"Acharya","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.11.014","article-title":"Real-world comorbidities of atopic dermatitis in the US adult ambulatory population","volume":"86","author":"Roh","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.337","article-title":"Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP","volume":"131","author":"Birlea","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2008.0578","article-title":"Association between IL4 (-590), ACE (I)\/(D), CCR5 (Delta32), CTLA4 (+49) and IL1-RN (VNTR in intron 2) gene polymorphisms and vitiligo","volume":"19","author":"Pehlivan","year":"2009","journal-title":"Eur J Dermatol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.2012.167.issue-2","article-title":"Interleukin-4 genetic variants correlate with its transcript and protein levels in patients with vitiligo","volume":"167","author":"Imran","year":"2012","journal-title":"Br J Dermatol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2013.2009","article-title":"Interleukin-4 (-590 C>T) and interleukin-4 receptor (Q551R A>G) gene polymorphisms in Saudi patients with vitiligo","volume":"23","author":"Al-Shobaili","year":"2013","journal-title":"Eur J Dermatol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.00897.x","article-title":"Association of thymic stromal lymphopoietin gene -847C>T polymorphism in generalized vitiligo","volume":"18","author":"Cheong","year":"2009","journal-title":"Exp Dermatol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.07.018","article-title":"Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-\u03b2) in patients with vitiligo","volume":"66","author":"Khan","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-016-1675-2","article-title":"IL-33 circulating serum levels are increased in patients with non-segmental generalized vitiligo","volume":"308","author":"Vaccaro","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"B128","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cca.2013.05.005","article-title":"T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo","volume":"424","author":"Tembhre","year":"2013","journal-title":"Clin Chim Acta"},{"key":"B129","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4103\/ejdv.ejdv_46_22","article-title":"Assessment of serum interleukin-13 level in vitiligo patients and its correlation to disease severity","volume":"43","author":"Tawfik","year":"2023","journal-title":"Egypt J Dermatol Venerol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1164124","article-title":"Mitophagy and immune infiltration in vitiligo: evidence from bioinformatics analysis","volume":"14","author":"Luo","year":"2023","journal-title":"Front Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.37349\/ei","article-title":"The two faces of mast cells in vitiligo pathogenesis","volume":"1","author":"Katayama","year":"2021","journal-title":"Explor Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.031","article-title":"Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.12.028","article-title":"Misbalanced CXCL12 and CCL5 chemotactic signals in vitiligo onset and progression","volume":"137","author":"Rezk","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/cells12020217","article-title":"Pathogenic th2 cytokine profile skewing by IFN-\u03b3-responding vitiligo fibroblasts via CCL2\/CCL8","volume":"12","author":"Jin","year":"2023","journal-title":"Cells"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/35006097","article-title":"Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1","volume":"404","author":"Gu","year":"2000","journal-title":"Nature"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1984","article-title":"Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ T(H)2 cells","volume":"12","author":"Islam","year":"2011","journal-title":"Nat Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12531","article-title":"Role of epidermal \u03b3\u03b4 T-cell-derived interleukin 13 in the skin-whitening effect of Ginsenoside F1","volume":"23","author":"Han","year":"2014","journal-title":"Exp Dermatol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.331","article-title":"IL-4 inhibits the melanogenesis of normal human melanocytes through the JAK2-STAT6 signaling pathway","volume":"133","author":"Choi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/sj.jid.5700940","article-title":"Modulation of keratinocyte-derived MMP-9 by IL-13: a possible role for the pathogenesis of epidermal inflammation","volume":"128","author":"Purwar","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-016-1713-0","article-title":"Senescence in the lesional fibroblasts of non-segmental vitiligo patients","volume":"309","author":"Rani","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"B141","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jid.2017.06.033","article-title":"Vitiligo skin: exploring the dermal compartment","volume":"138","author":"Kovacs","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3390\/diagnostics10110878","article-title":"p16ink4a positivity of melanocytes in non-segmental vitiligo","volume":"10","author":"Lee","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093232","article-title":"Interferon-\u03b3 induces senescence in normal human melanocytes","volume":"9","author":"Wang","year":"2014","journal-title":"PloS One"},{"key":"B144","doi-asserted-by":"publisher","first-page":"111779","DOI":"10.1016\/j.mad.2023.111779","article-title":"Acceleration of melanocyte senescence by the proinflammatory cytokines IFN\u03b3 and TNF\u03b1 impairs the repigmentation response of vitiligo patients to narrowband ultraviolet B (NBUVB) phototherapy","volume":"211","author":"Dong","year":"2023","journal-title":"Mech Ageing Dev"},{"key":"B145","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41368-022-00180-6","article-title":"Interleukin-13 promotes cellular senescence through inducing mitochondrial dysfunction in IgG4-related sialadenitis","volume":"14","author":"Zhu","year":"2022","journal-title":"Int J Oral Sci"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19132","article-title":"Vitiligo induced by dupilumab treatment: A case series","volume":"37","author":"Ren","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"adv00581","DOI":"10.2340\/actadv.v101.545","article-title":"Rapid enlargement of vitiligo vulgaris after initiation of dupilumab for atopic dermatitis: A case report","volume":"101","author":"Takeoka","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.03.025","article-title":"Vitiligo during dupilumab therapy","volume":"36","author":"Picone","year":"2023","journal-title":"JAAD Case Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1405215\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T04:24:20Z","timestamp":1716956660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1405215\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":148,"alternative-id":["10.3389\/fimmu.2024.1405215"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1405215","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"article-number":"1405215"}}